Overview of World Federation of Hemophilia Treatment Guidelines, 3rd Edition

The 2020 World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia, 3rd edition, provides evidence- and consensus-based recommendations for clinical practice and is an update to the 2005 and 2012 editions, Based upon a systematic review of the literature and a rigorous consensus-based Delphi process of hemophilia care experts and well-informed patients, WHF’s recommendations reflect:

Unparalleled emergence of novel therapeutics
Improvement in hemostasis
Progress in genetic analysis
Advances in laboratory monitoring
Inclusion of patient-reported assessment outcomes

The 3rd edition of the WFH Treatment Guidelines is endorsed by the Asian-Pacific Society on Thrombosis and Hemostasis, European Haemophilia Consortium, and National Hemophilia Foundation (USA).

In this webinar, we will provide an overview of the WFH Treatment Guidelines, 3rd edition, and discuss the unprecedented progress made in hemophilia diagnosis and treatment, focusing on three sections which have seen the greatest evolution since the 2nd edition and showcasing their potential to impact the management of hemophilia.

Learning Objectives:

1. Describe the updated WFH Treatment Guidelines for three areas of hemophilia clinical practice: hemostatic agents, inhibitors, and prophylaxis.

2. Discuss the chronic care model and the evolution from acute, episodic, and reactive care towards longitudinal, preventive, and community-based integrative care.

3. List examples of opportunities highlighted in the updated guidelines to improve the standard of diagnosis and care for people with hemophilia.